Yukei Oo

Yukei Oo

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
PLPei Xuan Lee
Pei Xuan Lee
DTDonald Heng Rong Ting
Donald Heng Rong Ting
CBClement Peng Hee Boey
Clement Peng Hee Boey
ETEunice Tze Xin Tan
Eunice Tze Xin Tan
JCJanice Zuo Hui Chia
Janice Zuo Hui Chia
SASylvie Alonso
Sylvie Alonso
Dengue is a major public health concern in the tropical and subtropical world, with no effective treatment. The controversial live attenuated virus vaccine Dengvaxia has boosted the pursuit of subunit vaccine approaches, and nonstructural protein 1 (NS1) has recently emerged as a promising candidate. However, we found that NS1 immunization or passive transfer of NS1 antibodies failed to confer protection in symptomatic dengue mouse models using two non–mouse-adapted DENV2 strains that are highly virulent. Exogenous administration of purified NS1 also failed to worsen in vivo vascular leakage in sublethally infected mice. Neither method of NS1 immune neutralization changed the disease outcome of a chimeric strain expressing a vascular leak-potent NS1. Instead, virus chimerization involving the prME structural region indicated that these proteins play a critical role in driving in vivo fitness and virulence of the virus, through induction of key proinflammatory cytokines. This work highlights that the pathogenic role of NS1 is DENV strain dependent, which warrants reevaluation of NS1 as a universal dengue vaccine candidate.

19 April 2021 in EMBO Reports
Verified
Journal Article
Closed access
PDF file
ZLZe Qin Lim
Ze Qin Lim
QNQing Yong Ng
Qing Yong Ng
YOYukei Oo
Yukei Oo
Justin Jang Hann CHUJustin Jang Hann CHU
Justin Jang Hann CHU
SNShi Yan Ng
Shi Yan Ng
SASylvie Alonso
Sylvie Alonso

7 November 2023 in Antiviral Research
Verified
Journal Article
Open access
GPGeraldine Nadya Putri
Geraldine Nadya Putri
CGChandra Sekhar Gudla
Chandra Sekhar Gudla
MSMayas Singh
Mayas Singh
CNChin Huan Ng
Chin Huan Ng
FIFakhriedzwan Fitri Haji Idris
Fakhriedzwan Fitri Haji Idris
SASylvie Alonso
Sylvie Alonso
With approximately 3.8 billion people at risk of infection in tropical and sub-tropical regions, Dengue ranks among the top ten threats worldwide. Despite the potential for severe disease manifestation and the economic burden it places on endemic countries, there is a lack of approved antiviral agents to effectively treat the infection. Flavonoids, including baicalein, have garnered attention for their antimicrobial properties. In this study, we took a rational and iterative approach to develop a series of baicalein derivatives with improved antiviral activity against Dengue virus (DENV). Compound 11064 emerged as a promising lead candidate, exhibiting antiviral activity against the four DENV serotypes and representative strains of Zika virus (ZIKV) in vitro, with attractive selectivity indices. Mechanistic studies revealed that Compound 11064 did not prevent DENV attachment at the cell surface, nor viral RNA synthesis and viral protein translation. Instead, the drug was found to impair the post-receptor binding entry steps (endocytosis and/or uncoating), as well as the late stage of DENV infection cycle, including virus assembly/maturation and/or exocytosis. The inability to raise DENV resistant mutants, combined with significant antiviral activity against an unrelated RNA virus (Enterovirus-A71) suggested that Compound 11064 targets the host rather than a viral protein, further supporting its broad-spectrum antiviral potential. Overall, Compound 11064 represents a promising antiviral candidate for the treatment of Dengue and Zika.

13 April 2023 in Cells
Verified
Journal Article
Open access
PDF file
HOHsiao Hui Ong
Hsiao Hui Ong
JLJing Liu
Jing Liu
YOYukei Oo
Yukei Oo
MTMark Thong
Mark Thong
De Yun WangDe Yun Wang
De Yun Wang
JOJoe Ong
Joe Ong
Our previous study revealed that prolonged human rhinovirus (HRV) infection rapidly induces antiviral interferons (IFNs) and chemokines during the acute stage of infection. It also showed that expression levels of RIG-I and interferon-stimulated genes (ISGs) were sustained in tandem with the persistent expression of HRV RNA and HRV proteins at the late stage of the 14-day infection period. Some studies have explored the protective effects of initial acute HRV infection on secondary influenza A virus (IAV) infection. However, the susceptibility of human nasal epithelial cells (hNECs) to re-infection by the same HRV serotype, and to secondary IAV infection following prolonged primary HRV infection, has not been studied in detail. Therefore, the aim of this study was to investigate the effects and underlying mechanisms of HRV persistence on the susceptibility of hNECs against HRV re-infection and secondary IAV infection. We analyzed the viral replication and innate immune responses of hNECs infected with the same HRV serotype A16 and IAV H3N2 at 14 days after initial HRV-A16 infection. Prolonged primary HRV infection significantly diminished the IAV load of secondary H3N2 infection, but not the HRV load of HRV-A16 re-infection. The reduced IAV load of secondary H3N2 infection may be explained by increased baseline expression levels of RIG-I and ISGs, specifically MX1 and IFITM1, which are induced by prolonged primary HRV infection. As is congruent with this finding, in those cells that received early and multi-dose pre-treatment with Rupintrivir (HRV 3C protease inhibitor) prior to secondary IAV infection, the reduction in IAV load was abolished compared to the group without pre-treatment with Rupintrivir. In conclusion, the antiviral state induced from prolonged primary HRV infection mediated by RIG-I and ISGs (including MX1 and IFITM1) can confer a protective innate immune defense mechanism against secondary influenza infection.

17 February 2026 in EMBO Reports
Verified
Journal Article
Closed access
PDF file
ZLZe Qin Lim
Ze Qin Lim
QNQing Yong Ng
Qing Yong Ng
YOYukei Oo
Yukei Oo
JCJustin Jang Hann Chu
Justin Jang Hann Chu
SNShi Yan Ng
Shi Yan Ng
SASylvie Alonso
Sylvie Alonso